Modality
Multispecific
MOA
EGFRi
Target
SOS1
Pathway
STING
Atopic DermRettRSV
Development Pipeline
Preclinical
~Jun 2015
→ ~Sep 2016
Phase 1
~Dec 2016
→ ~Mar 2018
Phase 2
Jun 2018
→ Mar 2030
Phase 2Current
NCT06225684
2,951 pts·RSV
2025-02→2030-03·Completed
NCT06118508
2,946 pts·Rett
2018-06→TBD·Active
5,897 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-03-194.0y awayPh3 Readout· RSV
Trial Timeline
Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
P2/3
Active
P2/3
Complet…
Catalysts
Ph3 Readout
2030-03-19 · 4.0y away
RSV
ActiveCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06225684 | Phase 2/3 | RSV | Completed | 2951 | Safety |
| NCT06118508 | Phase 2/3 | Rett | Active | 2946 | HbA1c |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Niranesiran | Johnson & Johnson | Phase 2 | KIF18A | |
| JNJ-5094 | Johnson & Johnson | Phase 2/3 | GIP-R | |
| Terarelsin | AbbVie | Preclinical | SOS1 | |
| Ribofutibatinib | AstraZeneca | Phase 2/3 | SOS1 | |
| GSK-2051 | GSK | Phase 1 | PSMA | |
| Voxacagene | Gilead Sciences | Phase 2/3 | SOS1 | |
| GIL-8529 | Gilead Sciences | Phase 1/2 | JAK1 | |
| SRP-9822 | Sarepta | Phase 3 | SOS1 | |
| 207-2754 | Samsung Biologics | Phase 1/2 | KRASG12D | |
| Mavuratamab | Blueprint Medicines | NDA/BLA | BET |